In last trading session, Rubius Therapeutics Inc. (NASDAQ:RUBY) saw 1.78 million shares changing hands with its beta currently measuring 2.53. Company’s recent per share price level of $0.45 trading at -$0.04 or -7.21% at ring of the bell on the day assigns it a market valuation of $49.85M. That closing price of RUBY’s stock is at a discount of -4304.44% from its 52-week high price of $19.82 and is indicating a discount of -4.44% from its 52-week low price of $0.47. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.95 million shares which gives us an average trading volume of 3.06 million if we extend that period to 3-months.
Rubius Therapeutics Inc. (NASDAQ:RUBY) trade information
Upright in the red during last session for losing -7.21%, in the last five days RUBY remained trading in the red while hitting it’s week-highest on Friday, 09/16/22 when the stock touched $0.45 price level, adding 34.79% to its value on the day. Rubius Therapeutics Inc.’s shares saw a change of -95.30% in year-to-date performance and have moved -34.26% in past 5-day. Rubius Therapeutics Inc. (NASDAQ:RUBY) showed a performance of -38.14% in past 30-days. Number of shares sold short was 2.41 million shares which calculate 6.34 days to cover the short interests.
Rubius Therapeutics Inc. (RUBY) estimates and forecasts
Statistics highlight that Rubius Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -90.94% of value to its shares in past 6 months, showing an annual growth rate of 16.14% while that of industry is 1.80. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 27.30% in the current quarter and calculating 57.40% increase in the next quarter.
Rubius Therapeutics Inc. is more likely to be releasing its next quarterly report between November 07 and November 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Rubius Therapeutics Inc. (NASDAQ:RUBY)’s Major holders
Insiders are in possession of 5.52% of company’s total shares while institution are holding 87.21 percent of that, with stock having share float percentage of 92.30%. Investors also watch the number of corporate investors in a company very closely, which is 87.21% institutions for Rubius Therapeutics Inc. that are currently holding shares of the company. Flagship Pioneering Inc. is the top institutional holder at RUBY for having 38.51 million shares of worth $17.51 million. And as of Jun 29, 2022, it was holding 42.62% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 13.53 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 14.97% of outstanding shares, having a total worth of $6.15 million.
On the other hand, Fidelity Growth Company Fund and Smallcap World Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2022, the former fund manager was holding 4.55 million shares of worth $2.07 million or 5.03% of the total outstanding shares. The later fund manager was in possession of 2.25 million shares on Jun 29, 2022, making its stake of worth around $1.02 million in the company or a holder of 2.49% of company’s stock.